A detailed history of Spire Wealth Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Spire Wealth Management holds 20,055 shares of VRTX stock, worth $9.4 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
20,055
Previous 20,651 2.89%
Holding current value
$9.4 Million
Previous $8.4 Million 0.23%
% of portfolio
0.28%
Previous 0.29%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

SELL
$407.69 - $446.08 $242,983 - $265,863
-596 Reduced 2.89%
20,055 $8.38 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $1.47 Million - $1.76 Million
4,274 Added 26.1%
20,651 $8.4 Million
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $2.3 Million - $2.46 Million
-6,796 Reduced 29.33%
16,377 $5.69 Million
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $500,242 - $559,888
-1,591 Reduced 6.42%
23,173 $8.15 Million
Q1 2023

May 09, 2023

BUY
$283.23 - $323.1 $1.04 Million - $1.18 Million
3,664 Added 17.36%
24,764 $7.8 Million
Q4 2022

Feb 03, 2023

SELL
$285.76 - $321.48 $193,173 - $217,320
-676 Reduced 3.1%
21,100 $6.09 Million
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $1.44 Million - $1.61 Million
-5,276 Reduced 19.5%
21,776 $6.31 Million
Q2 2022

Jul 22, 2022

SELL
$234.96 - $292.55 $2.59 Million - $3.22 Million
-11,007 Reduced 28.92%
27,052 $7.62 Million
Q1 2022

Apr 18, 2022

BUY
$221.42 - $260.97 $7.84 Million - $9.24 Million
35,416 Added 1339.99%
38,059 $9.94 Million
Q4 2021

Jan 14, 2022

BUY
$177.01 - $223.45 $305,696 - $385,898
1,727 Added 188.54%
2,643 $580,000
Q3 2021

Oct 22, 2021

SELL
$181.39 - $202.99 $81,625 - $91,345
-450 Reduced 32.94%
916 $166,000
Q2 2021

Jul 26, 2021

SELL
$187.49 - $221.1 $630,341 - $743,338
-3,362 Reduced 71.11%
1,366 $275,000
Q1 2021

May 21, 2021

BUY
$207.02 - $241.31 $978,790 - $1.14 Million
4,728 New
4,728 $1.02 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.